宣亞國際(300612.SZ):經營範圍擬新增”軟件開發“
格隆匯 8 月 20日丨宣亞國際(300612.SZ)公佈,公司根據經營發展的實際需要,擬在公司經營範圍中增加“軟件開發”,即擬變更後的經營範圍為:軟件開發、技術開發、技術推廣、技術轉讓、技術諮詢、技術服務;營銷策劃、企業策劃;計算機系統服務;企業管理諮詢;經濟貿易諮詢;承辦展覽展示活動;市場信息調查諮詢;設計、製作、代理、發佈廣告;出租辦公用房、物業管理。具體範圍以工商登記機關核准的內容為準,同時《公司章程》中的相應條款作同步修訂。
公司董事會同意將公司的企業類型擬由“股份有限公司(台港澳與境內合資、上市)”變更為“股份有限公司(上市公司)”,具體以經公司登記機關核准的變更登記結果為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.